7 results about "Sufentanil" patented technology

The present invention belongs to the technical field of medicine. Provided are a compound, and a preparation method therefor and the use thereof. The compound has a structure as shown in formula I. The compound of the present invention not only has efficient sedative, hypnotic and / or anesthetic effects, and the ability to control status epilepticus, but also exhibits an analgesic effect, and can reduce or avoid the use of opioid analgesics such as fentanyl, alfentanil, sufentanil or remifentanil in clinical application, thereby reducing the occurrence of adverse reactions such as circulatory depression, respiratory depression, urinary retention and pruritus caused by opioid analgesics.

The present application relates to a deuterium-labeled psychoactive substance, which has a chemical structural formula as shown in the description.The present application also provides a preparation method of the deuterium-labeled psychoactive substance, which comprises the following steps: (1) removing the methyl group of sufentanil under the action of a demethylating agent to generate a demethylated intermediate; (2) reacting the demethylated intermediate with a deuterated methyl reagent to generate the deuterium-labeled sufentanil.The present application also provides the use of the deuterium-labeled sufentanil in detecting the content of sufentanil in biological samples or environmental samples.

The present invention belongs to the technical field of medicine. Provided are a compound, and a preparation method therefor and the use thereof. The compound has a structure as shown in formula I. The compound of the present invention not only has efficient sedative, hypnotic and / or anesthetic effects, and can control status epilepticus, but also has an analgesic effect, and can reduce or avoid the use of opioid analgesics such as fentanyl, alfentanil, sufentanil or remifentanil in clinical application, thereby reducing the occurrence of adverse reactions such as circulatory inhibition, respiratory inhibition, urinary retention and pruritus caused by opioid analgesics.

An aqueous composition for intranasal administration by spray including a mixture of (a) sufentanil, a salt and / or analogs thereof and (b) ketamine, a salt and analogs thereof in solution. Also, an aqueous composition for intranasal administration by spray including (a) sufentanil, a salt and / or analogs thereof in solution and an aqueous composition for intranasal administration by spray including (b) ketamine, a salt and / or analogs thereof in solution, for use in a method for the treatment or prevention of pain in a child. The composition is useful for treating or preventing pain in a child of 17 years or younger. The composition is delivered from a nasal spray device to treat or prevent the pain such as procedural pain in a child.

To provide preparation of sufentanil citrate and sufentanil base.SOLUTION: Provided herein are processing methods corresponding to forming sufentanil citrate from sufentanil base. One process comprises forming sufentanil citrate in the presence of a polar non-aqueous solvent. Other processes comprise forming sufentanil citrate in the presence of water. One aspect of the present disclosure encompasses a process for forming sufentanil citrate from sufentanil base in the presence of a polar non-aqueous solvent.SELECTED DRAWING: None

To provide a formulation of sufentanyl citrate and sufentanyl base. [Solution] The present specification describes a processing method corresponding to the formation of sufentanyl citrate from a sufentanyl salt. One process comprises forming sufentanyl citrate in the presence of a polar non-aqueous solvent. Another process comprises forming sufentanyl citrate in the presence of water. One aspect of this disclosure comprises a process for forming sufentanyl citrate from a sufentanyl base in the presence of a polar non-aqueous solvent.

The invention discloses a closed-loop transcranial stimulation system and a closed-loop transcranial stimulation method. 0.3 mg of scopolamine and 3 mg of midazolam are intramuscularly injected before an operation; after a patient enters a room, sufentanil is subjected to intravenous injection induced by right subclavian vein and radial artery puncture general anesthesia, propofol is subjected to target-control infusion, the plasma target concentration is 3.0 mu g / mL, vecuronium bromide is 0.15 mg / kg, tracheal intubation is performed after 5 min, general anesthesia maintains target-control infusion of propofol, and after the patient enters the room, the target-control infusion of propofol is performed. A TMS stimulation coil electricity-magnetism-heat-stress model, a single-phase and double-phase pulse discharge circuit model and a neuron dynamic response model under the action of a TMS are established, and the influence of TMS system parameters on space-time distribution characteristics of an intracranial induced electric field and neuron membrane potential can be accurately expressed. Behavior perception and system auditory stimulation are combined to be applied to nursing intervention of severe craniocerebral injury coma patients, self-repairing and consciousness awakening of the brain functions of the patients can be effectively promoted, and meanwhile recovery of limb functions and daily life ability of the patients is facilitated.